Sanofi Suit Against Mylan To Stay In EpiPen MDL, For Now
Sanofi's allegations that Mylan illegally protected its EpiPen monopoly will remain tied into consumers' related multidistrict litigation in Kansas, a federal judge ruled Wednesday, as he found splitting the similar antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article